|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this phase I/II study, 14 high-risk disease-free ovarian (OC) and breast cancer (BC) patients after completion of standard therapies were vaccinated with MUC1, ErbB2 and carcinoembryonic antigen (CEA) HLA-A2+-restricted peptides and Montanide.
|
26892612 |
2016 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression.
|
23525470 |
2013 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
On multivariable analyses, subtype changes were more common in high-grade breast cancer (P < 0.001; OR, 1.077; 95% CI, 1.031-1.113) and CEA ≥ 5 (P = 0.032; OR, 2.658; 95% CI, 1.088-6.490).
|
31742206 |
2019 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally, the tumor markers for breast cancer (CA 15-3 and CEA) were analyzed in both groups.
|
31412345 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, serum levels of the carbohydrate antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) were determined preoperatively in 364 breast cancer patients with no clinical signs of metastasis.
|
11553856 |
2001 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen (CEA) is an important oncomarker for the detection of breast cancer.
|
31247453 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Their low sensitivity and specificity preclude the use of serum markers such as the MUC-1 mucin glycoproteins (CA 15.3, BR 27.29) and carcinoembryonic antigen in the diagnosis of early breast cancer.
|
16254457 |
2005 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the antitumor potential of a novel viral agent, an attenuated strain of measles virus deriving from the Edmonston vaccine lineage, genetically engineered to produce carcinoembryonic antigen (CEA) against breast cancer.
|
16642271 |
2006 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While CK-18 is a marker for epithelia in general, CEA is mainly employed in the detection of gastrointestinal and breast carcinomas.
|
7541767 |
1995 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
At 90% specificity of the assay (CEA, 2.13 ng/mg protein), the corresponding sensitivity for breast cancer detection was 62%, according to the receiver operating characteristic curve drawn.
|
15508191 |
2004 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
|
29701836 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although expression of CEA largely ceases prior to birth, several human epithelial cancers, including colorectal, gastric, squamous esophageal, and breast carcinomas have been known to overexpress CEA, suggesting its potential as an immunotherapeutic target.
|
30666318 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Authors investigated the expression level of miRNAs (miRNA-21, miRNA-126, and miRNA-155) to evaluate their role as diagnostic and prognostic markers for breast cancer compared with other commonly used protein-based markers (CEA and CA15-3).
|
30825229 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the tumor markers currently available for breast cancer detection include carcinoembryonic antigen (CEA), carbohydrate antigen 15.3 (CA15.3), and carbohydrate antigen 27.29 (CA27.29) exhibited certain limitations.
|
19787229 |
2009 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors.
|
28228086 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen (CEA) is one of the tumor markers available for evaluating disease progression status after initial therapy and monitoring subsequent treatment modalities in colorectal, gastrointestinal, lung, and breast carcinoma.
|
29611386 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While miR-34a provides valuable information for diagnosis and staging, combination with tumor markers CA15-3 or CEA improves the sensitivity for breast cancer detection.
|
29854296 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This meta-analysis showed that elevated serum CA15-3 or CEA was associated with poor DFS and OS in patients with breast cancer, and they should be tested anytime if possible.
|
29854028 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simultaneous detection of multiple mRNA markers CK19, CEA, c-Met, Her2/neu and hMAM with membrane array, an innovative technique with a great potential for breast cancer diagnosis.
|
16289546 |
2006 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To identify surrogate markers for prognosis of breast cancer patients with non-pathological complete response (non-pCR) to neoadjuvant chemotherapy (NAC), our investigation focused on the serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA15-3) as well as clinicopathological factors both before and after NAC.
|
29936704 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preoperative CA15-3 and CEA elevation are significant prognostic factors for luminal breast cancer, but they were not significant factors for TNBC.
|
31312932 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sensitivity of this assay was significantly higher than that of the assay involving conventional tumor markers (CEA and/or CA15-3) for stages I (24 vs. 8%) and II (26 vs. 8%) breast cancer and similar to that of the assay involving the conventional tumor markers for stage III (18 vs. 19%) and metastatic breast cancers (55 vs. 59%).
|
21594664 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The area under curve (AUC) of CEA, CA153, and FER for distinguishing patients with breast cancer and subjects with non-breast cancer was 0.688 (95% CI: 0.656-0.721), 0.609 (95% CI: 0.574-0.645), and 0.623 (95% CI: 0.586-0.660), respectively.
|
30843272 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two tests in lung cancer (ERCC1 and EGFR) and 1 test in breast cancer (CEA/CA15-3/CA27.29) were identified as top research priorities.
|
22274803 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The positivity of miR-21, miR-155, and miR-365 was high compared to CA 153 and CEA in breast cancer.
|
28203552 |
2017 |